Olema Pharmaceuticals, Inc.
Olema Oncology is a cancer medicines company dedicated to improving patient care in breast cancer and beyond. They focus on developing safer, more effective, and convenient treatments for metastatic breast cancer, driven by a passionate team of oncology experts. Their mission is to create innovative medicines that help people living with cancer feel better, longer.
Industries
Nr. of Employees
medium (51-250)
Olema Pharmaceuticals, Inc.
Products
Oral complete estrogen receptor antagonist / selective ER degrader (clinical candidate)
An oral small-molecule candidate designed to fully antagonize estrogen receptor signaling and promote receptor degradation; advanced through preclinical studies and into Phase 1–3 clinical testing for ER+/HER2- metastatic breast cancer.
Selective KAT6 inhibitor (preclinical/early clinical candidate)
A small-molecule inhibitor targeting KAT6 family epigenetic enzymes with demonstrated anti-tumor activity in preclinical models and combination potential with endocrine and cell-cycle therapies.
Oral complete estrogen receptor antagonist / selective ER degrader (clinical candidate)
An oral small-molecule candidate designed to fully antagonize estrogen receptor signaling and promote receptor degradation; advanced through preclinical studies and into Phase 1–3 clinical testing for ER+/HER2- metastatic breast cancer.
Selective KAT6 inhibitor (preclinical/early clinical candidate)
A small-molecule inhibitor targeting KAT6 family epigenetic enzymes with demonstrated anti-tumor activity in preclinical models and combination potential with endocrine and cell-cycle therapies.
Services
End-to-end clinical development services including protocol design, multi-center trial execution, dose-escalation/expansion studies, and pivotal Phase 3 trial operations.
In vivo pharmacology, xenograft and intracranial metastasis modeling, PK/PD studies, and sequencing-based translational assays to support candidate selection and clinical translation.
Regulatory planning to progress compounds through clinical development and guidance on expanded access policy considerations.
Management of collaborations with external pharmaceutical partners to design and run combination studies and co-develop clinical programs.
End-to-end clinical development services including protocol design, multi-center trial execution, dose-escalation/expansion studies, and pivotal Phase 3 trial operations.
In vivo pharmacology, xenograft and intracranial metastasis modeling, PK/PD studies, and sequencing-based translational assays to support candidate selection and clinical translation.
Regulatory planning to progress compounds through clinical development and guidance on expanded access policy considerations.
Management of collaborations with external pharmaceutical partners to design and run combination studies and co-develop clinical programs.
Expertise Areas
- ER-positive (ER+) breast cancer therapeutics
- Small-molecule oncology drug discovery
- Preclinical pharmacology and in vivo efficacy models
- Clinical trial management (Phase 1–3)
Key Technologies
- Complete estrogen receptor antagonism and selective ER degradation
- KAT6-targeted epigenetic inhibition
- Xenograft and intracranial metastasis in vivo models
- Precision run-on sequencing (PRO-Seq) and transcriptional profiling